Rigel Pharmaceuticals, Inc. has grown revenue 30% a year over three years and 14% a year over five. Revenue growth, 3-year annual rate: +30% (Biotechnology median +17%). Revenue growth, 5-year rate: +14%, growth has picked up over the last three years. Years of annual history on file: 17, FY2009 to FY2025, as filed.

RIGLRigel Pharmaceuticals, Inc.

Healthcare

$48.76+65% 1Y

$48.76

$25.4452 weeks$50.96

Is it growing?

Mixed

Neither accelerating nor breaking down: earnings up +211% year on year, but operating margin narrowing (−3.5 points).

1 good, 1 to watch, 1 neutral

Revenue trend+3% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +14% a year.

Earnings trend+211% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−3.5 points operating

Trailing-twelve-month operating margin, 31.1% now against 34.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is RIGL growing?

Rigel Pharmaceuticals, Inc. has grown revenue 30% a year over three years and 14% a year over five.

+30%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +14%
Revenue growth, 5-year rate · +30% over three · growth has picked up over the last three years
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›